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Abstract
Field cancerization involves the lateral spread of premalignant or malignant disease and contributes to the recur-
rence of head and neck tumors. The overall hypothesis underlying this work is that endothelial cells actively par-
ticipate in tumor cell invasion by secreting chemokines and creating a chemotactic gradient for tumor cells. Here
we demonstrate that conditioned medium from head and neck tumor cells enhance Bcl-2 expression in neovas-
cular endothelial cells. Oral squamous cell carcinoma-3 (OSCC3) and Kaposi’s sarcoma (SLK) show enhanced in-
vasiveness when cocultured with pools of human dermal microvascular endothelial cells stably expressing Bcl-2
(HDMEC–Bcl-2), compared to cocultures with empty vector controls (HDMEC–LXSN). Xenografted OSCC3 tumors
vascularized with HDMEC–Bcl-2 presented higher local invasion than OSCC3 tumors vascularized with control
HDMEC–LXSN. CXCL1 and CXCL8 were upregulated in primary endothelial cells exposed to vascular endothelial
growth factor (VEGF), as well as in HDMEC–Bcl-2. Notably, blockade of CXCR2 signaling, but not CXCR1, inhibited
OSCC3 and SLK invasion toward endothelial cells. These data demonstrate that CXC chemokines secreted by en-
dothelial cells induce tumor cell invasion and suggest that the process of lateral spread of tumor cells observed in
field cancerization is guided by chemotactic signals that originated from endothelial cells.
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Introduction
Head and neck cancer is the sixth most common malignancy in the
United States and has an overall incidence of 270 cases per million
[1,2]. Combination chemo, surgical, and radiation therapies have im-
proved local and regional control of head and neck cancer, yet treat-
ment of local recurrence, second primary tumors, and metastatic
disease continues to fail [3,4]. Field cancerization is the term used
to describe the high prevalence of multiple local second primary tu-
mors, multiple patches of premalignant or malignant disease, and the
incidence of synchronous distant tumors in the upper aerodigestive
tract that is frequently observed in head and neck tumors [4,5]. In-
deed, the high morbidity and frequency of recurrent disease observed
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in patients with head and neck cancer is explained, in part, by the abil-
ity of tumor cells to move laterally and persist outside the field of treat-
ment [5,6]. The understanding of the cell and molecular mechanisms
involved in tumor cell invasion and lateral spread may provide clues for
improved treatment strategies for patients with head and neck cancer.
The most common histologic subtype of head and neck cancer is
squamous cell carcinoma (HNSCC), which is characterized by the
high frequency of field cancerization [6,7]. We have recently reported
that Bcl-2 expression is approximately 60,000-fold higher in tumor-
associated endothelial cells of patients with HNSCC, compared to
Bcl-2 expression levels in endothelial cells from normal oral mucosa
[8]. To understand the role of Bcl-2 in neovascular endothelial cells,
we transduced human dermal microvascular endothelial cells
(HDMECs) with Bcl-2 and observed that these cells present enhanced
survival and increased angiogenic potential [9–11]. Xenografted head
and neck tumors vascularized with these cells showed enhanced tumor
microvessel density and accelerated tumor progression [10,11]. Inhibi-
tion of Bcl-2 function with subapoptotic concentrations of a small
molecule inhibitor of Bcl-2 (TW37 or BL193) had a strong antiangio-
genic effect that was functionally unrelated to Bcl-2’s effect as a pro-
survival protein [12]. Notably, Bcl-2 phosphorylates I-κB and activates
the NF-κB signaling pathway, leading to the upregulation of CXCL1
and CXCL8 expression in endothelial cells [10].
Chemokines are a group of small, structurally related chemotactic
proteins that contribute to tumor growth, cell migration, metastasis,
angiogenesis, and wound healing [13]. These chemokines are also
thought to be involved with the homing of tumor cells to specific
organs and tissues [13]. Recent evidence suggests that the expression
of chemokines and their receptors may predict where tumor cells go
after escaping from the primary site. Gene expression profiles of pri-
mary tumors have been able to predict lymphatic spread of oral squa-
mous cell carcinomas (OSCCs) [4,14–16]. Downregulation of
CCR6 in primary oral squamous carcinoma cells was correlated with
metastatic spread to lymph nodes [16], and increased levels of CCR7
mRNA in non–small lung cancer correlated with metastatic spread
to the lymph nodes [17]. High CXCR4 expression levels were cor-
related with increased metastatic potential of nasopharyngeal carci-
noma [15], and breast cancer patients with high CXCR4 levels in
the primary tumors had a significantly higher risk for metastasis to
lung and liver [18]. Taken together, these studies demonstrate that
chemokine-mediated signaling events have a direct impact on the pro-
cesses of tumor cell invasion and metastasis.
CXC chemokines have been evaluated in the saliva of patients
with oral preneoplastic lesions and OSCC patients [19]. Specifically,
the levels of CXCL6 and CXCL8 were significantly higher in patients
with OSCCs compared to oral preneoplastic lesion patients [19].
CXCL1 expression in OSCC correlated with increased microvessel
density and was associated with lymph node metastasis [20]. The ef-
fects of tumor-derived CXC chemokines on tumor cell invasion have
also been evaluated. CXCL8 produced in OSCC-conditioned me-
dium increased OSCC migration and invasion in vitro through ma-
trix metalloproteinase 7 upregulation [21]. Upregulation of CXCL8
in prostate cancer cells resulted in increased matrix metalloproteinase
9 expression and invasion both in vitro and in vivo [22]. Tumors were
larger and had significantly more lymph node metastasis in trans-
genic mice expressing CXCL8 (i.e., PC-3P(CXCL8) mice, compared
to control mice) [22].
Most studies reported in the literature have focused on the effects
of chemokines expressed by tumor cells on tumor cell invasion. Here,
we look at the process of tumor cell invasion from a different angle.
We hypothesize that chemokines secreted by endothelial cells gener-
ate a positive gradient toward blood vessels that favors tumor cell
movement away from its original site. We demonstrate that endothe-
lial cell Bcl-2 expression levels have a direct correlation with head and
neck tumor cell invasion in vitro and local recurrence in vivo and that
these effects are mediated by endothelial cell–derived CXCL1 and
CXCL8 signaling through tumor cell CXCR2.
Materials and Methods
Cell Culture
Oral squamous cell carcinoma-3 (OSCC3; gift of M. Lingen, Uni-
versity of Chicago, IL), University of Michigan–squamous cell carci-
nomas (UM-SCC-17B, UM-SCC-74A, and UM-SCC-11A; gift of
T. Carey, University of Michigan) and Kaposi’s sarcoma (SLK; gift of
G. Nunez, University of Michigan) cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS), 1% l-glutamine, and 0.05% penicillin and strepto-
mycin (Invitrogen Corporation, Carlsbad, CA). OSCC3-Luc cells were
generated through retrovirus infection, as described [10,24], and main-
tained in the DMEM/FBS supplemented with 1 mg/ml G418 (Fisher
Scientific, Pittsburgh, PA). Human dermal microvascular endothelial
cells (Cambrex, Walkersville, MD) were cultured in EGM2-MV me-
dium (Cambrex). Pools of primary human dermal microvascular endo-
thelial cells stably transduced with Flag-tagged Bcl-2 (HDMEC–Bcl-2)
and HDMEC–LXSN (empty vector controls) were generated with retro-
viruses and maintained in EGM2-MV supplemented with 250 μg/ml
G418, as described [9,11]. Multiple pools of HDMEC–LXSN and
HDMEC–Bcl-2 cells were generated and used in the experiments.
Western Blot and ELISA
Endothelial cell lysates were resolved by PAGE and membranes
were probed overnight with 4.6 μg/ml mouse anti-Flag (Sigma-
Aldrich, Atlanta, GA) to detect transduced Bcl-2; 0.25 μg/ml ham-
ster anti–Bcl-2 antibody (Pharmingen, San Diego, CA) to detect
endogenous Bcl-2 levels; 0.5 mg/ml mouse anti–human CXCR1
or mouse anti–human CXCR2 (Biosource, Camarillo, CA) at 4°C
overnight. Proteins were detected using peroxidase-conjugated sec-
ondary antibodies and bands were detected using enhanced chemilu-
minescence (Amersham, Sunnyvale, CA). ELISA for CXCL1 and
CXCL8 were performed according to the manufacturer’s instructions
(Quantikine; R&D Systems, Minneapolis, MN).
Sulforhodamine B Cell Proliferation Assay
HDMEC–LXSN (1.0 × 103), HDMEC–Bcl-2 (1.0 × 103),
OSCC3 (5.0 × 102), or SLK (5.0 × 102) cells were exposed to 1,
10, or 50 μg/ml anti-CXCR1, anti-CXCR2, or 50 μg/ml IgG
(R&D Systems) to evaluate the cytotoxic effects of the antibodies used
in the invasion experiments. After 48 hours, cells were fixed with 10%
trichloroacetic acid and stained with 0.4% sulforhodamine B (SRB)
solution as previously described [12]. Plates were read in a microplate
reader at 565 nm (Tecan, Salzburg, Austria). All data points were nor-
malized to untreated cells.
Coculture Invasion Assay
HDMEC–LXSN or HDMEC–Bcl-2 (3.0 × 104) were seeded in
24-well companion plates (Fisher Scientific) and allowed to attach
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overnight. Each well was fed with 400 μl of fresh EBM2 (no FBS or
growth factors) ± neutralizing antibodies to condition the medium
for 24 hours. A matrix consisting of a 1:1 mixture of growth factor
reduced Matrigel (BD Bioscience, Bedford, MA) and serum-free
DMEM was loaded onto 8.0-μm pore–sized inserts and was allowed
to solidify overnight. Twenty-four–hour serum-starved OSCC3 or
SLK cells (2.0 × 105) were loaded onto the membranes in 200 μl
of serum-free DMEM. A total of 1 μg/ml anti–CXCR1- and/or
anti–CXCR2-neutralizing antibodies (R&D Systems) or IgG2A iso-
type control (R&D Systems) were preincubated with tumor cells for
15 minutes. Tumor cells were then added to the membranes and al-
lowed to invade for 24 hours. Invaded cells were trypsinized, collected,
and stained with 2 μM Cell Tracker Green (Invitrogen) and fluores-
cence was read at 485/535 nm in a microplate reader (Tecan). Tripli-
cate wells per condition were evaluated, and the data shown represent
at least three independent experiments. All data points were normal-
ized to HDMEC–LXSN untreated control cells. Statistical significance
was determined using SigmaStat 2.0 software at P ≤ .05 using one-way
ANOVA followed by Tukey’s post hoc test or by Student’s t test.
Severe Combined Immunodeficient Mouse Model of
Tumor Invasion
OSCC3–Luc (1.0 × 105) + HDMEC–Bcl-2 or HDMEC–LXSN
(9.0 × 105) were seeded onto poly-l-lactic acid sponges in a 1:1 mix-
ture of growth factor reduced Matrigel and EGM2-MV. One scaffold
was implanted subcutaneously in the dorsal region of each severe
combined immunodeficient (SCID) mouse (5- to 7-week-old male
CB.17.SCID; Taconic, Germantown, NY) as previously described
[9–11,24,26]. Primary and secondary tumors were surgically retrieved
at 5 and 8 weeks after implantation. When secondary tumors reached
2000 mm3, mice were euthanized, and tumors were removed.
In Vivo Bioluminescence Imaging
In vivo bioluminescence imaging was performed on a cryogenically
cooled IVIS system coupled to a data acquisition software (Xenogen,
Hopkinton, MA) every 2 weeks at the University of Michigan Center
for Molecular Imaging. Before imaging, mice were anesthetized with
2% inhaled isoflurane, and luciferin potassium salt (Xenogen, Alameda,
CA) in PBS was administered intraperitoneally at a dose of 320 mg/kg
body weight. Mice were placed on a thermostated bed in the IVIS
chamber, and isoflurane was administered by a nose cone delivery sys-
tem. Ten minutes after the luciferin injection, a grayscale body surface
image was taken, followed by acquisition and overlay of the pseudo-
color image representing the emission of the active bioluminescence
in the implanted cells. Integration times of 30 seconds to 5 minutes were
used for luminescent acquisition. Images were analyzed with the Living-
Image software (Xenogen,Hopkinton,MA), and the light intensity from
the region of interest corresponding to the scaffold was measured in units
of photons/sec per cm2 for quantification of the relative number of
metabolically active tumor cells expressing luciferase [23,24].
Results
Endothelial Cell Bcl-2 Levels Have a Direct Correlation with
OSCC3 and SLK Tumor Cell Invasion In Vitro
To provide baseline information for this study, we exposed primary
endothelial cells to recombinant human vascular endothelial growth
factor (VEGF165) or to the conditioned medium of a panel of head
and neck tumor cells, and evaluated Bcl-2 expression levels. We ob-
served that both, VEGF and all head and neck tumor cells tested
here, induced Bcl-2 expression in the neovascular endothelial cells
(Figure 1A). To evaluate the effect of Bcl-2 expression levels in endo-
thelial cells on head and neck tumor cell invasion, we transduced
Figure 1. Upregulated Bcl-2 expression in endothelial cells enhances tumor cell invasion in vitro. (A) Western blot analysis of Bcl-2
expression in HDMECs exposed to 0 or 50 ng/ml rhVEGF165 for 24 hours, or in HDMEC exposed to tumor cell–conditioned medium
from UM-SCC-17B, OSCC3, SLK, and UM-SCC-74A cells for 24 hours using a monoclonal anti–Bcl-2 antibody. (B) Western blot analysis
to characterize Bcl-2 expression in three independent pools of HDMEC stably transduced with Bcl-2, or with empty retroviral vector
(LXSN) using a mouse anti-Flag antibody. (C) Graph depicting OSCC3 or SLK invasion toward HDMEC–LXSN or HDMEC–Bcl-2 cells
in vitro. *P ≤ .05. Data represent mean values (± SD) of three independent experiments.
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these cells with flag-tagged Bcl-2 using a retroviral vector that allows
for selection with neomycin (i.e., LXSN), as described [10]. Several
pools of selected endothelial cells expressing Bcl-2 (Figure 1B) were
generated, evaluated for Bcl-2 expression by Bcl-2 immunoblot anal-
ysis, and used in the experiments presented in this article. A method
for evaluation of tumor cell invasion toward endothelial cell–generated
chemotactic stimuli was established by coculturing these cells in
24-well companion plates. Endothelial cells (HDMEC–Bcl-2 or
HDMEC–LXSN) were plated in the bottom well, and head and neck
tumor cells were cultured on transwells (8-μm pore membrane) coated
with growth factor reduced Matrigel. We observed that OSCC3 had
increased invasion toward HDMEC–Bcl-2 compared to invasion to-
ward empty vector control HDMEC–LXSN (Figure 1C ). To evaluate
how specific the response was to tumor cell type, we repeated the ex-
periment with SLK, and observed very similar trends (Figure 1C ).
Endothelial Cell Bcl-2 Levels Have a Direct Correlation with
Head and Neck Tumor Cell Invasion In Vivo
To evaluate if the trends for enhanced invasive potential of
OSCC3 mediated by endothelial cells expressing Bcl-2 in vitro trans-
late into higher tumor invasiveness in vivo, we developed an immu-
nodeficient mouse–based model of human head and neck tumor cell
invasion. This model is conceptually based on the SCID mouse
model of human tumor angiogenesis, in which we engineer human
tumors vascularized with human functional blood vessels that anasto-
mize with the mouse vasculature [10–12,24]. In this model, we seed
primary human endothelial cells together with head and neck cancer
cells in highly porous biodegradable scaffolds, implant them in the sub-
cutaneous of SCID mice, and observe tumor progression and tumor
angiogenesis. Here, we used luciferase-tagged OSCC3 cells to allow
us to evaluate tumor progression noninvasively over time, as described
[24–26]. To evaluate the effect of Bcl-2 expression levels in endothelial
cells on tumor cell invasion, we removed the primary tumors 35 days
after implantation of the cells and evaluated local recurrence of the tu-
mors by in vivo bioluminescence for a period of 3 weeks (Figure 2A).
This experimental design allowed us to test the hypothesis that high
Bcl-2 levels in primary tumor–associated endothelial cells contribute
to lateral spread of the tumor cells and field cancerization. We imaged
each mouse over time during primary tumor progression and after re-
moval of the primary tumor (Figure 2B). Notably, 3 weeks after pri-
mary tumor removal, the local bioluminescence in mice that received
OSCC3 tumors vascularized with HDMEC–Bcl-2 was significantly
higher than the bioluminescence in mice that had OSCC3 tumors vas-
cularized with control HDMEC–LXSN cells (Figure 2C ). In Figure 3,
we present bioluminescence data from all mice included in a represen-
tative experiment. As can be seen, median bioluminescence was higher
28 days after implantation in primary tumors vascularized with
HDMEC–Bcl-2 cells (Figure 3A). Immediately after primary tumor re-
moval, the local in vivo bioluminescence presented a similar drop in the
two experimental conditions tested here, which represents our best ef-
forts to remove completely the primary tumor (Figure 3B). However,
3 weeks after primary tumor removal, mice that were originally im-
planted with tumors vascularized with HDMEC–Bcl-2 cells now pres-
ent higher local recurrence, as represented by higher bioluminescence
values (P < .05) (Figure 3C ). Indeed, each mouse in the HDMEC–
Bcl-2/OSCC3 group had higher values of local bioluminescence at this
late time point than its HDMEC–LXSN/OSCC3 counterpart. Histo-
logic analysis demonstrated that recurrent tumors reproduced the mor-
phologic features of the primary tumors (Figure 4) and corroborated
our in vivo bioluminescence findings (Figure 3). Of note is that, in this
experiment, one mouse of the HDMEC–LXSN/OSCC3 group died
after the 28-day bioluminescence imaging.
CXCR2 Signaling, But Not CXCR1, Is Involved in Endothelial
Cell–Mediated Head and Neck Tumor Cell Invasion
In search for the understanding of the molecular mechanisms in-
volved in the effects of endothelial cell Bcl-2 on head and neck tumor
cell invasion, we evaluated the CXC chemokine signaling axis. The
expression levels of CXCL8 and CXCL1 were significantly upregu-
lated in endothelial cells treated with VEGF165, compared to untreated
controls (Figure 5, A and B). Furthermore, the expression levels of
these two chemokines were also upregulated in independent pools
of endothelial cells transduced with Bcl-2 compared to endothelial
cells transduced with the empty retroviral vector LXSN (Figure 5,
A and B). Enhanced expression of these two chemotactic proteins
by the endothelial cells could potentially induce tumor cell invasion
if these cells express the correlated CXC receptors. Whereas CXCL8
signals through CXCR1 and CXCR2, CXCL1 only signals through
Figure 2. Evaluation of tumor progression over time by in vivo bioluminescence. (A) Experimental design used for acquisition of data
presented in Figures 2 and 3. (B) In vivo bioluminescent images of one mouse implanted with HDMEC–LXSN + OSCC3 cells and one
mouse implanted with HDMEC–Bcl-2 + OSCC3 cells over time (i.e., 14, 28, 34, 41 and 56 days after implantation). (C) Graph depicting
in vivo bioluminescent values after 56 days. *P ≤ .05. Data presented in C correspond to the analysis of six mice per condition.
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CXCR2 [13]. Evaluation of the expression levels of CXCR1 and
CXCR2 in a panel of head and neck cancer cells demonstrated that all
cells examined express fairly high levels of both receptors (Figure 5C ).
To evaluate the role of CXCR1 and CXCR2 on endothelial cell me-
diated tumor cell invasion, we performed blocking experiments with
commercially available neutralizing antibodies in vitro. We observed
that blockade of CXCR2 signaling abrogated the invasive potential of
both tumor cells evaluated, reducing it to baseline levels (Figure 6, B
and E ). In contrast, blockade of CXCR1 signaling did not prevent the
invasion of the tumor cells, particularly SLK cells, toward HDMEC–
Bcl-2 (Figure 6, A and D). When we blocked both, CXCR1 and
CXCR2 signaling, tumor cell invasion was reduced to levels below
baseline (Figure 6, C and F ). To ensure that the reduced invasion ob-
served with blockade of CXC receptor signaling was not simply due
to antibody-induced cell death, we performed a viability test using
the SRB method (Figure 6G ). These experiments demonstrated that
the antibodies used here do not induce death of either the tumor
or the endothelial cells and allowed us to conclude that the reduction
in tumor cell invasion observed with the CXCR2 antibody is due to
functional inhibition of cell motility on blockade of this chemotactic
signaling axis.
Discussion
The distinctive ability of head and neck cancer cells to migrate and
persist outside of the field of treatment leads to the high incidence of
recurrence observed in patients with this disease. The phenomenon
of field cancerization observed in head and neck tumors can be
caused either by molecular events affecting several cells from different
locations at the same time or by molecular events in a single clonal
Figure 3. Upregulation of Bcl-2 expression in endothelial cells enhances xenograft tumor recurrence. (A–C) In vivo bioluminescent
images of each mouse implanted with HDMEC–LXSN + OSCC3 cells and each mouse implanted with HDMEC–Bcl-2 + OSCC3 cells;
and corresponding scatter plots showing each individual data point and the median bioluminescence value (horizontal line). (A) Biolu-
minescence of primary tumors (28 days). (B) Bioluminescence immediately after removal of the primary tumors (35 days). (C) Biolumi-
nescence of the local recurrences (56 days).
Neoplasia Vol. 10, No. 2, 2008 Endothelial Cells and Field Cancerization Warner et al. 135
progenitor that is capable of widespread clonal expansion or lateral
spread [27,28]. These mechanisms do not have to be mutually ex-
clusive. The process of local tumor spread has been associated with
epithelial–mesenchymal transition, a conserved morphogenic pro-
cess that involves loss of E-cadherin function that contribute to the
migration of individual tumor cells [28–30]. Here, we focused on the
potential role of a molecular crosstalk initiated by endothelial cells
that result in tumor cell movement away from its original niche.
This study was conceptually based on our finding that Bcl-2 in-
duces CXCL1 and CXCL8 expression through activation of the NF-
κB signaling pathway [10]. We reasoned that, besides the reported
proangiogenic effect of this signaling cascade through an autocrine
loop [10], this pathway could also affect tumor cell invasion because
CXCL1 and CXCL8 are potent chemoattractant factors for tumor
cells [30]. Indeed, here we observed a vigorous induction of invasion
of a head and neck cancer cell line (OSCC3) induced by endothelial
cells expressing Bcl-2 compared to controls. We observed a similar
trend when different pools of HDMEC–Bcl-2 cells and other tumor
cell lines (e.g. SLK) were tested, demonstrating that this phenome-
non is not specific to one cell line.
These initial findings suggested that endothelial cells might play
a role in the lateral spread of head and neck tumors, but a more
Figure 4. Primary and recurrent xenograft tumors show similar histologic features. Hematoxylin and eosin staining of a (A) primary and
(B) recurrent tumor retrieved from a mouse implanted with HDMEC–LXSN + OSCC3 cells. (C) Primary and (D) recurrent tumor retrieved
from a mouse implanted with HDMEC–Bcl-2 + OSCC3 cells. Original magnification, 400×.
Figure 5. Head and neck tumor cells express CXCR1 and CXCR2. (A) Graph showing CXCL8 and (B) CXCL1 expression in endothelial
cells treated with 50.0 ng/ml rhVEGF165 for 24 hours, two independent pools of HDMEC–Bcl-2, HDMEC–LXSN, or untreated controls. *P≤
.05 relative to untreated controls. (C) Western blot analysis of CXCR1 and CXCR2 expression in endothelial and a panel of tumor cells.
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conclusive observation required in vivo data. To address the role of
endothelial cells in local invasion of head and neck tumors, we de-
vised a new experimental strategy. We seeded human endothelial cells
and human squamous cell carcinoma cells in biodegradable scaffolds
to generate human tumors vascularized with human blood vessels, as
previously described [10,31]. The tumor cells were transduced with
luciferase to allow us to evaluate tumor progression over time by bio-
luminescence [24,26]. After 35 days, we removed the primary tumors
composed of human endothelial and OSCC3 tumor cells and ob-
served local tumor recurrence by bioluminescence. This method
Figure 6. Blockade of CXCR2, but not CXCR1, signaling prevents tumor cell invasion toward endothelial cells expressing Bcl-2. (A–F)
Graphs characterizing the effect of blockade of CXCR1 and/or CXCR2 signaling on (A–C) SLK, or (D–F) OSCC3 tumor cell invasion in vitro.
Cells were exposed to 1.0 μg/ml anti-CXCR1 (A and D), 1.0 μg/ml anti-CXCR2 (B and E), or to both anti-CXCR1 and anti-CXCR2 (C and F) at
the same time. As controls, we exposed cells to 1.0 μg/ml nonspecific isotype-matched IgG, or left cells untreated. Data represent mean
values (± SD) of three independent experiments. Statistical significance (P ≤ .05) is depicted by lowercase letters: a tumor cell invasion
is significantly higher toward HDMEC–Bcl-2 or HDMEC–Bcl-2 + IgG than toward HDMEC–LXSN; b tumor cell invasion is significantly
higher toward HDMEC–Bcl-2 or HDMEC–Bcl-2 + IgG than toward HDMEC–Bcl-2 + anti-CXCR2 or HDMEC–Bcl-2 + anti-CXCR1 + anti-
CXCR2. (G) SRB analysis of cells exposed to the same conditions as above for determination of the effects of the antibodies on cell
number. Data represent mean values (± SD) of two independent experiments.
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allowed us to single out the impact of Bcl-2 expression in the endo-
thelial cells that vascularized the original tumors on local tumor spread,
because all other factors (i.e., host and tumor cells) were identical in
the experimental conditions. These experiments led us to conclude
that tumor-associated endothelial cells have a direct impact on tumor
cell invasion and lateral spread.
The removal of the primary tumors from the mice that we per-
formed here attempts to mimic the surgeon’s best efforts to remove
completely primary tumors from head and neck cancer patients. In-
deed, our in vivo bioluminescence analysis demonstrated that, imme-
diately after tumor removal, the presence of tumor cells was minimal
and similar in both experimental conditions. However, the mice that
received primary tumors vascularized with HDMEC–Bcl-2 clearly
showed enhanced local recurrence. The increased rate of recurrence
can only be attributed to the enhanced local invasion of the primary
tumors. From these experiments, we conclude that factors secreted
by endothelial cells have a direct impact on head and neck tumor cell
invasion and contribute to field cancerization. These results may help
to explain the high rate of recurrence observed in head and neck can-
cer patients that receive conventional therapy [32–35]. In search for a
mechanistic link between Bcl-2 expression in endothelial cells and
tumor cell invasion, we explored the potential involvement of
CXC chemokine signaling. Indeed, untransduced endothelial cells
exposed to VEGF, a known physiological inducer of Bcl-2 expression
[9], and endothelial cells transduced with Bcl-2 have marked up-
regulation of CXCL1 and CXCL8 expression [8,10]. Furthermore,
all tumor cells evaluated here showed expression of CXCR1 and
CXCR2. Notably, blockade of CXCR2 signaling led to inhibition
of endothelial cell initiated tumor cell invasion in vitro. In contrast,
blockade of CXCR1 did not affect tumor cell invasion. Taken together,
these data demonstrate that the effect of Bcl-2 expression on head and
neck tumor cell invasion is mediated by endothelial cell derived CXC
chemokines signaling through tumor cell CXCR2.
In conclusion, we demonstrate that CXC chemokines secreted by
tumor-associated endothelial cells induce tumor cell invasion
through CXCR2. We also showed that Bcl-2 upregulation correlates
with increased expression of CXCL1 and CXCL8 in endothelial cells.
The relevance of these findings to human disease is underscored by
the observation that the expression levels of Bcl-2 in the endothelial
cells of patients with head and neck tumors are several thousand
times higher than in the endothelial cells of normal oral mucosa
[8]. These data provide a mechanism for the lateral spread of head
and neck tumors that challenge the current paradigm, because these
results position the neovascular endothelial cells as the source of a
chemotactic gradient that will induce tumor cell movement away
from its original niche. This work may also shed light on the mecha-
nisms underlying field cancerization of other tumors, such as colon,
breast, and ovarian cancers [36–38]. Importantly, these data suggest
that antiangiogenic therapies targeted at the blockade of this pathway
may decrease the rate of local recurrence and minimize the morbidity
associated with field cancerization.
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